Original Article
Bone Marrow Transplantation (2006) 37, 1087–1091. doi:10.1038/sj.bmt.1705390; published online 8 May 2006
Conditioning Regimens
The modification of high-dose therapy shortens the duration of neutropaenia by delay of leucocyte nadir
T Kiefer1, W H Krüger1, F Schüler1, C Lotze1, C Hirt1 and G Dölken1
1Department of Internal Medicine C (Haematology and Oncology, Marrow Transplantation), Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany
Correspondence: Dr WH Krüger, Medizinische Klinik C (Hämatologie und Onkologie, Transplantationszentrum), Ernst-Moritz-Arndt-Universität-Greifswald, Ferdinand-Sauerbruch-Stra
e, Greifswald 17475, Germany. E-mail: william.krueger@uni-greifswald.de
Received 15 September 2005; Revised 30 March 2006; Accepted 5 April 2006; Published online 8 May 2006.
Abstract
Infections during neutropaenia contribute still significantly to mortality and morbidity after high-dose therapy and autologous stem cell transplantation. Further acceleration of haemopoietic recovery seems impossible for biological reasons. Another approach to shorten neutropaenia could be to remove drugs from high-dose therapy protocols with strong contribution to immunosuppression and neutropaenia and unproven antineoplastic activity. In this retrospective matched-pair analysis, conventional busulphan/cyclophosphamide (Bu/Cy) high-dose therapy was compared to single-agent busulphan conditioning before autologous stem cell transplantation. This modification led to a significant shorter neutropaenic interval by protraction of cell decrease and to a significant mitigation of neutropaenia. After single-agent busulphan conditioning, leucocytes dropped below 1/nl at median 1.5 days later when compared to the patients from the busulphanBu/Cy control group (P=0.001). In a significant percentage of patients (n=6, 60%) leucocytes did not fall below 0.5 cells/nl at any time. In contrast, all patients from the Bu/Cy control group experienced deep neutropaenia (P=0.004). Thrombocytopaenia and requirement for transfusions of platelets or red cells were not influenced. Antineoplastic activity seemed to be preserved as determined by survival analysis. In conclusion, modification of high-dose regimen with the intention to shorten neutropaenia with preserved antitumour activity could be an approach to reduce infection-related morbidity and mortality and to consider economic necessities.
Keywords:
high-dose therapy, autologous stem cell transplantation, conditioning therapy, neutropaenia, infection
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance
Bone Marrow Transplantation Review
RESEARCH
Journal of Cerebral Blood Flow & Metabolism Original Article
Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis
Bone Marrow Transplantation Original Article
Bone Marrow Transplantation Original Article
The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans
Bone Marrow Transplantation Letter

